Counting the burden: atopic dermatitis and health-related quality of life

ALI Faraz, V Jui, AY Finlay - Acta dermato-venereologica, 2020‏ - pmc.ncbi.nlm.nih.gov
Atopic dermatitis is the most prevalent chronic inflammatory skin condition globally. The
burden of atopic dermatitis on children and adults is extensive and there is also significant …

Interleukin 17A: toward a new understanding of psoriasis pathogenesis

CW Lynde, Y Poulin, R Vender, M Bourcier… - Journal of the American …, 2014‏ - Elsevier
Molecular and cellular understanding of psoriasis pathogenesis has evolved considerably
over the last 30 years beginning in the early 1980s when psoriasis was thought to be a skin …

[HTML][HTML] Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

D Thaçi, A Blauvelt, K Reich, TF Tsai… - Journal of the American …, 2015‏ - Elsevier
Background Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has
shown superior efficacy to etanercept with similar safety in moderate to severe plaque …

Comparison of long‐term drug survival and safety of biologic agents in patients with psoriasis vulgaris

R Gniadecki, B Bang, LE Bryld, L Iversen… - British Journal of …, 2015‏ - academic.oup.com
Background Drug survival (time to drug discontinuation) has recently emerged as an
important parameter reflecting the long‐term therapeutic performance in a real‐life setting …

PASI 90 response: the new standard in therapeutic efficacy for psoriasis

L Puig - Journal of the European Academy of Dermatology and …, 2015‏ - Wiley Online Library
In a non‐life‐threatening disease such as psoriasis, treatment goals should be referred to
the improvement in severity and extent of the disease and their impact on patients' perceived …

Malignancy risk and recurrence with psoriasis and its treatments: a concise update

S Geller, H Xu, M Lebwohl, B Nardone… - American journal of …, 2018‏ - Springer
Psoriasis is a common inflammatory cutaneous disease that affects approximately 120
million people worldwide. Systemic treatments have significantly improved disease burden …

Hidradenitis suppurativa (HS) prevalence, demographics and management pathways in Australia: a population-based cross-sectional study

M Calao, JL Wilson, L Spelman, L Billot, D Rubel… - PloS one, 2018‏ - journals.plos.org
Background Hidradenitis Suppurativa (HS) is a painful, chronic inflammatory skin disease.
Global estimates of prevalence vary between 0.03% and 4% of the population. Our main aim …

[HTML][HTML] Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis …

C Tehlirian, RSP Singh, V Pradhan, ES Roberts… - Journal of the American …, 2022‏ - Elsevier
Background Psoriasis treatments lack durable efficacy and have inconvenient
administration, highlighting the need for new therapies. Objective To evaluate the efficacy …

Psoriatic arthritis for dermatologists

A Gottlieb, JF Merola - Journal of Dermatological Treatment, 2020‏ - Taylor & Francis
Psoriatic arthritis (PsA) affects up to one-third of patients with psoriasis. It is the major
comorbidity of psoriasis because of the likelihood that loss of function and permanent …

JAK inhibitors in psoriatic disease

M Megna, L Potestio, A Ruggiero… - Clinical, Cosmetic …, 2023‏ - Taylor & Francis
Psoriasis is now considered to be the cutaneous phenotype of a systemic inflammatory
condition, recognized under the term Psoriatic Disease (PsD). PsD has several …